ERBB2 and neoplasm: With the aim to increase the visibility of tumor cells to NK cells, three bispecific immunoligands carrying a HER2-specific scFv and the ECD of B7-H6, AICL or PVR were generated to trigger NK cells via the activating receptors NKp30, NKp80 or DNAM-1, respectively.